Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

NCT01507831 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2341

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Placebo (for alirocumab)
DRUG: Alirocumab
DRUG: Lipid-Modifying Therapy (LMT)

Sponsor

Sanofi

Collaborators

[object Object]